The Role of IntraNasal Insulin in Regulating HepaTic Lipid COntent in HUMANS

NCT02164032 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Healthy Subjects

Interventions

DRUG: Intranasal insulin administration
DRUG: Insulin Dilution Buffer (Novo Nordisk)
OTHER: 1H magnetic resonance spectroscopy

Sponsor

Medical University of Vienna